RT Journal Article
SR Electronic
T1 A novel germline EGFR variant p.R831H causes predisposition to familial CDK12-mutant prostate cancer with tandem duplicator phenotype
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.23.20027045
DO 10.1101/2020.02.23.20027045
A1 Kaiyu Qian
A1 Gang Wang
A1 Lingao Ju
A1 Jiyan Liu
A1 Hang Zheng
A1 Yingao Zhang
A1 Liang Chen
A1 Yaoyi Xiong
A1 Yongwen Luo
A1 Yejinpeng Wang
A1 Tianchen Peng
A1 Fangjin Chen
A1 Dongmei Liu
A1 Xuefeng Liu
A1 Yi Zhang
A1 Yu Xiao
A1 Xinghuan Wang
YR 2020
UL http://medrxiv.org/content/early/2020/02/25/2020.02.23.20027045.abstract
AB 5-10% of total prostate cancer (PCa) cases are hereditary. Particularly, immunocheckpoint inhibitor-sensitive tandem duplicator phenotype (TDP) accounts for 6.9% PCa cases, whereas genetic susceptibility genes remain completely unknown. We identified a Chinese family with two PCa patients, in which the PCa phenotype co-segregated with a rare germline variant EGFRR831H. Patient-derived conditionally reprogrammed cells (CRC) exhibited increased EGFR and AKT phosphorylation, and a sensitivity to EGFR antagonist Afatinib in migration assays, suggesting the EGFR allele was constitutively active. Both EGFRR831H-mutant tumors contained biallelic CDK12 inactivation, together with prominent tandem duplication across the genome. These somatic mutations could be detected in urine before surgery. Analysis of public databases showed a significant correlation between mutation status of EGFR and CDK12. Taken together, our genetic and functional analyses identified a previously undescribed link between EGFR and prostate cancer.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported in part by grants from the Chinese Central Special Fund for Local Science and Technology Development of Hubei Province (2018ZYYD023), Science and Technology Department of Hubei Province Key Project (2018ACA159), and Wuhan Science and Technology Bureau Key Project (2018061005132294). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.BAFB-allele frequencyCOSMICCatalogue of somatic mutations in cancercfDNACell-free DNACRCConditionally reprogrammed cellCNVCopy-number-variedFFPEFormalin-fixed paraffin-embeddedGWASGenome-wide association studiesIHCImmunohistochemistryORFOpen reading framep-AKTPhosphorylated AKTp-EGFRPhosphorylated EGFRPCaProstate cancerPI-RADSProstate imaging reporting and data systemPSAProstate-specific antigenRTRoom temperatureSNVShort-nucleic-acid-variationTDPTandem duplicator phenotypeTCGAThe cancer genome atlasVAFVariant allele frequency